Results
Piramal Pharma Q4 Revenue Flat, FY26 PAT at -₹326Cr
Piramal Pharma reported flat Q4 revenue of ₹2,752Cr, with a full-year decline of 3% to ₹8,869Cr, impacted by CDMO destocking and soft ex-US anesthesia sales.
The company recorded a full-year net loss
